Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sarepta Therapeutics Q3 Adj. EPS $(0.13) Beats $(0.81) Estimate, Sales $399.356M Beat $338.710M Estimate

Author: Benzinga Newsdesk | November 03, 2025 04:09pm
Sarepta Therapeutics (NASDAQ:SRPT) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.81) by 84.05 percent. This is a 120.31 percent decrease over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $399.356 million which beat the analyst consensus estimate of $338.710 million by 17.91 percent. This is a 14.52 percent decrease over sales of $467.172 million the same period last year.

Posted In: SRPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist